Biomedical Engineering Reference
In-Depth Information
62. Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Relation of ventila-
tory impairment and of chronic mucus hypersecretion to mortality from
obstructive lung disease and from all causes. Thorax 1990; 45(8):579-585.
63. Sherman CB, Xu X, Speizer FE, Ferris BG Jr, Weiss ST, Dockery DW. Long-
itudinal lung function decline in subjects with respiratory symptoms. Am Rev
Respir Dis 1992; 146(4):855-859.
64. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion
with FEV1 decline and chronic obstructive pulmonary disease morbidity.
Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996;
153(5):1530-1535.
65. Miravitlles M, Guerrero T, Mayordomo C, Sanchez-Agudo L, Nicolau F,
Segu JL. Factors associated with increased risk of exacerbation and hospital
admission in a cohort of ambulatory COPD patients: a multiple logistic regres-
sion analysis. The EOLO Study Group. Respiration 2000; 67(5):495-501.
66. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote
FEV(l) decline in current smokers but not ex-smokers with mild chronic
obstructive pulmonary disease: results from the lung health study. Am J
Respir Crit Care Med 2001; 164(3):358-364.
67. Rogers DF. Motor control of airway goblet cells and glands. Respir Physiol
2000; 125(1-2):129-144.
68. Rogers DF. Motor control of airway goblet cells and glands. Respir Physiol
2001; 125(1-2):129-144.
69. Cammer P, Strandberg K, Philipson K. Increased mucociliary transport by
cholinergic stimulation. Arch Environ Health 1974; 29(4):220-224.
70. Berger J, Albert RE, Sanborn K, Lippmann M. Effects of atropine and metha-
choline on deposition and clearance of inhaled particles in the donkey. J
Toxicol Environ Health 1978; 4(4):587-604.
71. Gatto LA. Cholinergic and adrenergic stimulation of mucociliary transport in
the rat trachea. Respir Physiol 1993; 92(2):209-217.
72. Pavia D, Sutton PP, Lopez-Vidriero MT, Agnew JE, Clarke SW. Drug effects
on mucociliary function. Eur J Respir Dis Suppl 1983; 128(Pt l):304-317.
73. Tamaoki J, Chiyotani A, Tagaya E, Sakai N, Konno K. Effect of long term
treatment with oxitropium bromide on airway secretion in chronic bronchitis
and diffuse panbronchiolitis. Thorax 1994; 49(6):545-548.
74. Hasani A, Toms N, Creer DD, Agnew JE, Dilworth JP, Sarno M. Effect of
inhaled tiotropium on tracheobronchial clearance in patients with COPD.
Eur Respir J 2001; 18(Suppl 33):P1678.
75. Rogers DF. Pharmacological regulation of the neuronal control of airway
mucus secretion. Curr Opin Pharmacol 2002; 2(3):249-255.
76. Rogers DF. Tachykinin receptor antagonists for asthma and COPD. Expert
Opin Ther Patents 2001; 11:1097-1121.
77. Mossberg B, Strandberg K, Philipson K, Camner P. Tracheobronchial clear-
ance and beta-adrenoceptor stimulation in patients with chronic bronchitis.
Scand J Respir Dis 1976; 57(6):281-289.
78. Mossberg B, Strandberg K, Philipson K, Camner P. Tracheobronchial clear-
ance in bronchial asthma: response to beta-adrenoceptor stimulation. Scand J
Respir Dis 1976; 57(3):119-128.
